Can Heat Shock Proteins Improve Immunotherapy?
This article was originally published in Start Up
Therapeutic vaccines derived from antigenic peptides have yet to demonstrate significant efficacy, particularly in cancer. Over the past eight years, a series of observations has led a small group of companies to believe that heat shock proteins possess unique properties that could make them useful adjuvants in vaccines designed to generate specific immune responses against cancers and infectious agents.
You may also be interested in...
Pfizer's acquisition of Hsp90 specialist Serenex is the biggest direct validation by Big Pharma in this up and coming oncology space. Hsp90, sometimes termed a master regulator, has quickly emerged as an important cancer target and Pfizer's endorsement can only give the field a boost.
The finding that hsp90, a "molecular chaperone" that shuttles proteins throughout cells and performs a critical role in the mitochondria of tumor cells could have a profound influence on the development of an emerging class of drugs. It may help explain the limited effectiveness of current hsp90 inhibitors, which do not get into the mitochondria. The authors of the paper describing the work show that an hsp90 inhibitor that does get into the mitochondria has profound cell-killing capabilities.
To improve antigen recognition, Mojave Therapeutics is harnessing the intracellular antigenic peptide chaperone function of heat shock proteins. It has created a universal cassette for antigen delivery using hsp's, which it calls Javelin technology, that is applicable for active immunotherapy of infectious diseases and cancer.